Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis
Statins are lipid-lowering drugs that prevent cardiovascular disease but tolerability is limited by severe side effects in muscles. Here the authors elucidate a liver-specific activation mechanism for bempedoic acid, a novel cholesterol-lowering drug, and show how it effectively reduces LDL-C and at...
Guardado en:
Autores principales: | Stephen L. Pinkosky, Roger S. Newton, Emily A. Day, Rebecca J. Ford, Sarka Lhotak, Richard C. Austin, Carolyn M. Birch, Brennan K. Smith, Sergey Filippov, Pieter H.E. Groot, Gregory R. Steinberg, Narendra D. Lalwani |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/1f66c328c6054aecb4400856a6c02de9 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
ATP-citrate lyase promotes axonal transport across species
por: Aviel Even, et al.
Publicado: (2021) -
Macrophage ATP citrate lyase deficiency stabilizes atherosclerotic plaques
por: Jeroen Baardman, et al.
Publicado: (2020) -
Publisher Correction: ATP-citrate lyase promotes axonal transport across species
por: Aviel Even, et al.
Publicado: (2021) -
Caspase-10 inhibits ATP-citrate lyase-mediated metabolic and epigenetic reprogramming to suppress tumorigenesis
por: Rajni Kumari, et al.
Publicado: (2019) -
mTORC2-AKT signaling to ATP-citrate lyase drives brown adipogenesis and de novo lipogenesis
por: C. Martinez Calejman, et al.
Publicado: (2020)